Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon Dec 11, 2020 3:34pm
65 Views
Post# 32090396

RE:Used to like the Goodman but

RE:Used to like the Goodman but
MarkJagr wrote:

Now I do not know. Not saying he is a Bad man but What I liked was his ability to find a drug or drug maker for A) 8-12% interest, plus B) 3% ownership, plus C) the rights to promote the drug for 5 years.  That's what I liked. 

I also liked the he could sit on $400 million in cash and NOT rushing off to make a deal just to make a deal. 

I did not like that he could not get along with the Israeli drug company. And I do not understand why the initial business model as I described above, had to be abandoned for a 300 million investment in a distribution network.

That's why I left Knight some two years ago. I just put in a tax season-bid at 4.55 hoping that I am wrong and that Tiredman is still a Godman with spunk and spark. 



Ya - still don't understand the story behind Meir and we probably never will.  I would believe Goodman's integrety and honesty ... I have no reason to doubt it. See the video for Goodman's side of the story.

https://www.bnnbloomberg.ca/company-news/video/knight-therapeutics-ceo-i-made-a-mistake-in-selecting-my-partner~1652451

I went to the annual meeting in 2018 to also hear Meir's side - to ask Meir questions.  Instead - he sent a rep in his place.  He was well aware that he could get the boot and decided to avoid the situation all together.  Meir played it wrong ... kinda made me angry that he sent a rep to say a few words just before voting.  Very unprofessional and absolutely inadequate.  He knew it was over ... that's why he didn't even come to the meeting (IMO).

------------

I would bet that when things start to move quickly ... they will continue to move quickly.  I just don't think we're there yet.  If we only knew when ... would make a world of difference to my average purchase price.  Hahaha!

Thanks for sharing MarkJagr.  Much appreciated.
<< Previous
Bullboard Posts
Next >>